Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu Biopharma Inc (NQ: AYTU )

2.950 +0.140 (+4.98%)
Streaming Delayed Price Updated: 2:38 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aytu Biopharma Inc

< Previous 1 2 3 Next >
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients
Via ACCESSWIRE
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
Via ACCESSWIRE
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect
Via ACCESSWIRE
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
Via ACCESSWIRE
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row
Via ACCESSWIRE
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023
Via ACCESSWIRE
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan
Via ACCESSWIRE
Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions
Via ACCESSWIRE
Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue
Via ACCESSWIRE
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso
Via ACCESSWIRE
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022
Via ACCESSWIRE
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs
Via ACCESSWIRE
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022
Via ACCESSWIRE
Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin
Via ACCESSWIRE
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
Via ACCESSWIRE
Aytu BioPharma to Participate in September 2022 Investor Conferences
Via ACCESSWIRE
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
Via ACCESSWIRE
Aytu BioPharma Announces Pricing of Public Offering
Via ACCESSWIRE
Aytu BioPharma Announces Launch of Public Offering
Via ACCESSWIRE
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Via ACCESSWIRE
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
Via ACCESSWIRE
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / July 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of... 
From Aytu BioPharma, Inc.
Via AccessWire
Exposures Product Safety
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History Strategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pneumonia ENGLEWOOD, CO / ACCESSWIRE / April 25, 2022 / Aytu... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / April 19, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S.... 
From Aytu BioPharma, Inc.
Via AccessWire
Exposures Product Safety
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)
ENGLEWOOD, CO / ACCESSWIRE / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
ENGLEWOOD, CO / ACCESSWIRE / March 22, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that management... 
From Aytu BioPharma, Inc.
Via AccessWire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.